|
1
|
Zhao X, Wu Q, Gong X, Liu J and Ma Y:
Osteosarcoma: A review of current and future therapeutic
approaches. Biomed Eng Online. 20:242021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Moukengue B, Lallier M, Marchandet L,
Baud'huin M, Verrecchia F, Ory B and Lamoureux F: Origin and
therapies of osteosarcoma. Cancers (Basel). 14:35032022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tsagozis P, Gonzalez-Molina J, Georgoudaki
AM, Lehti K, Carlson J, Lundqvist A, Haglund F and Ehnman M:
Sarcoma tumor microenvironment. Adv Exp Med Biol. 1296:319–348.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wei L and Wang J: Tumor-associated
macrophages promote pre-metastatic niche formation in ovarian
cancer. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 40:1138–1145. 2024.(In
Chinese). PubMed/NCBI
|
|
5
|
Fang J, Lu Y, Zheng J, Jiang X, Shen H,
Shang X, Lu Y and Fu P: Exploring the crosstalk between endothelial
cells, immune cells, and immune checkpoints in the tumor
microenvironment: new insights and therapeutic implications. Cell
Death Dis. 14:5862023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Devaraji M and Varghese Cheriyan B:
Immune-based cancer therapies: Mechanistic insights, clinical
progress, and future directions. J Egypt Natl Canc Inst. 37:622025.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Malone MK, Smrekar K, Park S, Blakely B,
Walter A, Nasta N, Park J, Considine M, Danilova LV, Pandey NB, et
al: Cytokines secreted by stromal cells in TNBC microenvironment as
potential targets for cancer therapy. Cancer Biol Ther. 21:560–569.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zeng J, Peng Y, Wang D, Ayesha K and Chen
S: The interaction between osteosarcoma and other cells in the bone
microenvironment: From mechanism to clinical applications. Front
Cell Dev Biol. 11:11230652023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen F, Liu J, Yang T, Sun J, He X, Fu X,
Qiao S, An J and Yang J: Analysis of intercellular communication in
the osteosarcoma microenvironment based on single cell sequencing
data. J Bone Oncol. 41:1004932023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Amarasekara DS, Kim S and Rho J:
Regulation of osteoblast differentiation by cytokine networks. Int
J Mol Sci. 22:28512021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen X, Wang Z, Duan N, Zhu G, Schwarz EM
and Xie C: Osteoblast-osteoclast interactions. Connect Tissue Res.
59:99–107. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Anloague A and Delgado-Calle J:
Osteocytes: New kids on the block for cancer in bone therapy.
Cancers(Basel). 15:26452023.PubMed/NCBI
|
|
13
|
Behzatoglu K: Osteoclasts in tumor
biology: Metastasis and epithelial-mesenchymal-myeloid transition.
Pathol Oncol Res. 27:6094722021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang Q, Liu J, Wu B, Wang X, Jiang Y and
Zhu D: Role of extracellular vesicles in osteosarcoma. Int J Med
Sci. 19:1216–1226. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jerez S, Araya H, Hevia D, Irarrázaval CE,
Thaler R, van Wijnen AJ and Galindo M: Extracellular vesicles from
osteosarcoma cell lines contain miRNAs associated with cell
adhesion and apoptosis. Gene. 710:246–257. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Feng X and Teitelbaum SL: Osteoclasts: New
insights. Bone Res. 1:11–26. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang G, Jian A, Zhang Y and Zhang X: A
New signature of sarcoma based on the tumor microenvironment
benefits prognostic prediction. Int J Mol Sci. 24:29612023.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou Y, Yang D, Yang Q, Lv X, Huang W,
Zhou Z, Wang Y, Zhang Z, Yuan T, Ding X, et al: Single-cell RNA
landscape of intratumoral heterogeneity and immunosuppressive
microenvironment in advanced osteosarcoma. Nat Commun. 11:63222020.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cersosimo F, Lonardi S, Bernardini G,
Telfer B, Mandelli GE, Santucci A, Vermi W and Giurisato E:
Tumor-associated macrophages in osteosarcoma: From mechanisms to
therapy. Int J Mol Sci. 21:52072020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Qin Q, Gomez-Salazar M, Tower RJ, Chang L,
Morris CD, McCarthy EF, Ting K, Zhang X and James AW: NELL1
regulates the matrisome to promote osteosarcoma progression. Cancer
Res. 82:2734–2747. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhu T, Han J, Yang L, Cai Z, Sun W, Hua Y
and Xu J: Immune microenvironment in osteosarcoma: Components,
therapeutic strategies and clinical applications. Front Immunol.
13:9075502022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu J, Ding L, Mei J, Hu Y, Kong X, Dai S,
Bu T, Xiao Q and Ding K: Dual roles and therapeutic targeting of
tumor-associated macrophages in tumor microenvironments. Signal
Transduct Target Ther. 10:2682025. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang Q, Liang X, Ren T, Huang Y, Zhang H,
Yu Y, Chen C, Wang W, Niu J, Lou J and Guo W: The role of
tumor-associated macrophages in osteosarcoma
progression-therapeutic implications. Cell Oncol (Dordr).
44:525–539. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hou C, Lu M, Lei Z, Dai S, Chen W, Du S,
Jin Q, Zhou Z and Li H: HMGB1 positive feedback loop between cancer
cells and tumor-associated macrophages promotes osteosarcoma
migration and invasion. Lab Invest. 103:1000542023. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ligon JA, Choi W, Cojocaru G, Fu W, Hsiue
EH, Oke TF, Siegel N, Fong MH, Ladle B, Pratilas CA, et al:
Pathways of immune exclusion in metastatic osteosarcoma are
associated with inferior patient outcomes. J Immunother Cancer.
9:e0017722021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Judge SJ, Darrow MA, Thorpe SW, Gingrich
AA, O'Donnell EF, Bellini AR, Sturgill IR, Vick LV, Dunai C,
Stoffel KM, et al: Analysis of tumor-infiltrating NK and T cells
highlights IL-15 stimulation and TIGIT blockade as a combination
immunotherapy strategy for soft tissue sarcomas. J Immunother
Cancer. 8:e0013552020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kleinberger M, Çifçi D, Paiato C, Tomasich
E, Mair MJ, Steindl A, Spiró Z, Carrero ZI, Berchtold L,
Hainfellner J, et al: Density and entropy of immune cells within
the tumor microenvironment of primary tumors and matched brain
metastases. Acta Neuropathol Commun. 13:342025. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lu X, Liu M, Yang J, Que Y and Zhang X:
Panobinostat enhances NK cell cytotoxicity in soft tissue sarcoma.
Clin Exp Immunol. 209:127–139. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shigehara K, Kawai N, Shirosaki T, Ebihara
Y, Murai A, Takaya A, Tokita S, Sasaki K, Shijubou N, Kubo T, et
al: The size of CD8+ infiltrating T cells is a prognostic marker
for esophageal squamous cell carcinoma. Sci Rep. 15:266382025.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen L, Huang H, Huang Z, Chen J, Liu Y,
Wu Y, Li A, Ge J, Fang Z, Xu B, et al: Prognostic values of
tissue-resident CD8+T cells in human hepatocellular
carcinoma and intrahepatic cholangiocarcinoma. World J Surg Oncol.
21:1242023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Noy R and Pollard JW: Tumor-associated
macrophages: From mechanisms to therapy. Immunity. 41:49–61. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kinker GS, Vitiello GAF, Ferreira WAS,
Chaves AS, Cordeiro de Lima VC and Medina TDS: B cell orchestration
of anti-tumor immune responses: A matter of cell localization and
communication. Front Cell Dev Biol. 9:6781272021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cao Y, Kong L, Zhai Y, Hou W, Wang J, Liu
Y, Wang C, Zhao W, Ji H and He P: Comprehensive analysis of
TRIM56′s prognostic value and immune infiltration in pan-cancer.
Sci Rep. 15:136732025. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lo Nigro C, Macagno M, Sangiolo D,
Bertolaccini L, Aglietta M and Merlano MC: NK-mediated
antibody-dependent cell-mediated cytotoxicity in solid tumors:
Biological evidence and clinical perspectives. Ann Transl Med.
7:1052019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Capuano C, Pighi C, Battella S, De
Federicis D, Galandrini R and Palmieri G: Harnessing CD16-mediated
NK cell functions to enhance therapeutic efficacy of
tumor-targeting mAbs. Cancers (Basel). 13:25002021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rodríguez-Nava C, Ortuño-Pineda C,
Illades-Aguiar B, Flores-Alfaro E, Leyva-Vázquez MA, Parra-Rojas I,
Del Moral-Hernández O, Vences-Velázquez A, Cortés-Sarabia K and
Alarcón-Romero LDC: Mechanisms of action and limitations of
monoclonal antibodies and single chain fragment variable (scFv) in
the treatment of cancer. Biomedicines. 11:16102023. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Khodayari H, Khodayari S, Ebrahimi E,
Hadjilooei F, Vesovic M, Mahmoodzadeh H, Saric T, Stücker W, Van
Gool S, Hescheler J and Nayernia K: Stem cells-derived natural
killer cells for cancer immunotherapy: Current protocols,
feasibility, and benefits of ex vivo generated natural killer cells
in treatment of advanced solid tumors. Cancer Immunol Immunother.
70:3369–3395. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shin E, Bak SH, Park T, Kim JW, Yoon SR,
Jung H and Noh JY: Understanding NK cell biology for harnessing NK
cell therapies: Targeting cancer and beyond. Front Immunol.
14:11929072023. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Prager I and Watzl C: Mechanisms of
natural killer cell-mediated cellular cytotoxicity. J Leukoc Biol.
105:1319–29. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang ML, Chen L, Li YJ and Kong DL:
PD-L1/PD-1 axis serves an important role in natural killer
cell-induced cytotoxicity in osteosarcoma. Oncol Rep. 42:2049–2056.
2019.PubMed/NCBI
|
|
41
|
Yang H, Zhao L, Zhang Y and Li FF: A
comprehensive analysis of immune infiltration in the tumor
microenvironment of osteosarcoma. Cancer Med. 10:5696–5711. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lazarova M and Steinle A: Impairment of
NKG2D-mediated tumor immunity by TGF-β. Front Immunol. 10:26892019.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chang X, Ma Z, Zhu G, Lu Y and Yang J: New
perspective into mesenchymal stem cells: Molecular mechanisms
regulating osteosarcoma. J Bone Oncol. 29:1003722021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Antoon R, Overdevest N, Saleh AH and
Keating A: Mesenchymal stromal cells as cancer promoters. Oncogene.
43:3545–3555. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zheng Y, Wang G, Chen R, Hua Y and Cai Z:
Mesenchymal stem cells in the osteosarcoma microenvironment: Their
biological properties, influence on tumor growth, and therapeutic
implications. Stem Cell Res Ther. 9:222018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhu G, Xia Y, Zhao Z, Li A, Li H and Xiao
T: LncRNA XIST from the bone marrow mesenchymal stem cell derived
exosome promotes osteosarcoma growth and metastasis through
miR-655/ACLY signal. Cancer Cell Int. 22:3302022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chen C, Xie L, Ren T, Huang Y, Xu J and
Guo W: Immunotherapy for osteosarcoma: Fundamental mechanism,
rationale, and recent breakthroughs. Cancer Lett. 500:1–10. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tu B, Du L, Fan QM, Tang Z and Tang TT:
STAT3 activation by IL-6 from mesenchymal stem cells promotes the
proliferation and metastasis of osteosarcoma. Cancer Lett.
325:80–88. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Deng Q, Li P, Che M, Liu J, Biswas S, Ma
G, He L, Wei Z, Zhang Z, Yang Y, et al: Activation of hedgehog
signaling in mesenchymal stem cells induces cartilage and bone
tumor formation via Wnt/β-catenin. Elife. 8:e502082019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Feng L, Chen Y and Jin W: Research
progress on cancer-associated fibroblasts in osteosarcoma. Oncol
Res. 33:1091–1103. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Duan W, Niu X, Liu Y and Tian W:
Rab27b-mediated CAFs derived exosomal miR-22-3p suppresses
ferroptosis and promotes cisplatin resistance in osteosarcoma. Cell
Signal. Sep 17–2025.(Epub ahead of print). View Article : Google Scholar
|
|
52
|
Lin L, Huang K, Guo W, Zhou C, Wang G and
Zhao Q: Conditioned medium of the osteosarcoma cell line U2OS
induces hBMSCs to exhibit characteristics of carcinoma-associated
fibroblasts via activation of IL-6/STAT3 signalling. J Biochem.
168:265–271. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lagerweij T, Pérez-Lanzón M and Baglio SR:
A preclinical mouse model of osteosarcoma to define the
extracellular vesicle-mediated communication between tumor and
mesenchymal stem cells. J Vis Exp. 569322018.PubMed/NCBI
|
|
54
|
Zhang Q, Fu L, Liang Y, Guo Z, Wang L, Ma
C and Wang H: Exosomes originating from MSCs stimulated with TGF-β
and IFN-γ promote Treg differentiation. J Cell Physiol.
233:6832–6840. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ruksha T and Palkina N: Role of exosomes
in transforming growth factor-β-mediated cancer cell plasticity and
drug resistance. Explor Target Antitumor Thery. 6:10023222025.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Su Z, Fang X and Duan H: The paradoxical
role of stem cells in osteosarcoma: From pathogenesis to
therapeutic breakthroughs. Front Oncol. 15:16434912025. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Yang C, Liu C, Xia C and Fu L: Clinical
applications of circulating tumor cells in metastasis and therapy.
J Hematol Oncol. 18:802025. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Fu Y, Xu Y, Liu W, Zhang J, Wang F, Jian
Q, Huang G, Zou C, Xie X, Kim AH, et al: Tumor-informed deep
sequencing of ctDNA detects minimal residual disease and predicts
relapse in osteosarcoma. EClinicalMedicine. 73:1026972024.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zhang Y, Ma Q, Liu T, Guan G, Zhang K,
Chen J, Jia N, Yan S, Chen G, Liu S, et al: Interleukin-6
suppression reduces tumour self-seeding by circulating tumour cells
in a human osteosarcoma nude mouse model. Oncotarget. 7:446–458.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Tian H, Cao J, Li B, Nice EC, Mao H, Zhang
Y and Huang C: Managing the immune microenvironment of
osteosarcoma: The outlook for osteosarcoma treatment. Bone Res.
11:112023. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Thuya WL, Cao Y, Ho PC, Wong AL, Wang L,
Zhou J, Nicot C and Goh BC: Insights into IL-6/JAK/STAT3 signaling
in the tumor microenvironment: Implications for cancer therapy.
Cytokine Growth Factor Rev. 85:26–42. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Dou B, Chen T, Chu Q, Zhang G and Meng Z:
The roles of metastasis-related proteins in the development of
giant cell tumor of bone, osteosarcoma and Ewing's sarcoma. Technol
Health Care. 29:91–101. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Paino F, La Noce M, Di Nucci D, Nicoletti
GF, Salzillo R, De Rosa A, Ferraro GA, Papaccio G, Desiderio V and
Tirino V: Human adipose stem cell differentiation is highly
affected by cancer cells both in vitro and in vivo: Implication for
autologous fat grafting. Cell Death Dis. 8:e25682017. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Perrot P, Rousseau J, Bouffaut AL, Rédini
F, Cassagnau E, Deschaseaux F, Heymann MF, Heymann D, Duteille F,
Trichet V and Gouin F: Safety concern between autologous fat graft,
mesenchymal stem cell and osteosarcoma recurrence. PLoS One.
5:e109992010. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Liu T, Ma Q, Zhang Y, Wang X, Xu K, Yan K,
Dong W, Fan Q, Zhang Y and Qiu X: Self-seeding circulating tumor
cells promote the proliferation and metastasis of human
osteosarcoma by upregulating interleukin-8. Cell Death Dis.
10:5752019. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Tzanakakis GN, Giatagana EM, Berdiaki A,
Spyridaki I, Hida K, Neagu M, Tsatsakis AM and Nikitovic D: The
role of IGF/IGF-IR-signaling and extracellular matrix effectors in
bone sarcoma pathogenesis. Cancers (Basel). 13:24782021. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Duan SL, Fu WJ, Jiang YK, Peng LS, Ousmane
D, Zhang ZJ and Wang JP: Emerging role of exosome-derived
non-coding RNAs in tumor-associated angiogenesis of tumor
microenvironment. Front Mol Biosci. 10:12201932023. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Li Y, Jiang D, Zhang ZX, Zhang JJ, He HY,
Liu JL, Wang T, Yang XX, Liu BD, Yang LL, et al: Colorectal cancer
cell-secreted exosomal miRNA N-72 promotes tumor angiogenesis by
targeting CLDN18. Am J Cancer Res. 13:3482–3499. 2023.PubMed/NCBI
|
|
69
|
Ning XY, Ma JH, He W and Ma JT: Role of
exosomes in metastasis and therapeutic resistance in esophageal
cancer. World J Gastroenterol. 29:5699–5715. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Pan W, Miao Q, Yin W, Li X, Ye W, Zhang D,
Deng L, Zhang J and Chen M: The role and clinical applications of
exosomes in cancer drug resistance. Cancer Drug Resist.
7:432024.PubMed/NCBI
|
|
71
|
Tian W, Niu X, Feng F, Wang X, Wang J, Yao
W and Zhang P: The promising roles of exosomal microRNAs in
osteosarcoma: A new insight into the clinical therapy. Biomed
Pharmacother. 163:1147712023. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Chen CC and Benavente CA: Exploring the
impact of exosomal cargos on osteosarcoma progression: Insights
into therapeutic potential. Int J Mol Sci. 25:5682024. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Li X, Rong K, Huang Y, Zhao Z, Xu C, Lin
L, Zhang Y, Yan Y, Huang W, Zhang Y, et al: Suppression of
miR-148a-3p can promote bone healing by enhancing
angiogenesis-osteogenesis coupling through the PI3K/Akt pathway.
FASEB J. 39:e709302025. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Pu F, Chen F, Zhang Z, Liu J and Shao Z:
Information transfer and biological significance of neoplastic
exosomes in the tumor microenvironment of osteosarcoma. Onco
Targets Ther. 13:8931–8940. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Wolf-Dennen K, Gordon N and Kleinerman ES:
Exosomal communication by metastatic osteosarcoma cells modulates
alveolar macrophages to an M2 tumor-promoting phenotype and
inhibits tumoricidal functions. Oncoimmunology. 9:17476772020.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Shimbo K, Miyaki S, Ishitobi H, Kato Y,
Kubo T, Shimose S and Ochi M: Exosome-formed synthetic microRNA-143
is transferred to osteosarcoma cells and inhibits their migration.
Biochem Biophys Res Commun. 445:381–387. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Hu Q, Zhu Y, Mei J, Liu Y and Zhou G:
Extracellular matrix dynamics in tumor immunoregulation: From tumor
microenvironment to immunotherapy. J Hematol Oncol. 18:652025.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Pattabiram S, Gangadaran P, Dhayalan S,
Chatterjee G, Reyaz D, Prakash K, Arun R, Rajendran RL, Ahn BC and
Aruljothi KN: Decoding the tumor microenvironment: Insights and new
targets from single-cell sequencing and spatial transcriptomics.
Curr Issues Mol Biol. 47:7302025. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Cui J, Dean D, Hornicek FJ, Chen Z and
Duan Z: The role of extracelluar matrix in osteosarcoma progression
and metastasis. J Exp Clin Cancer Res. 39:1782020. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Tian H, Wu R, Feng N, Zhang J and Zuo J:
Recent advances in hydrogels-based osteosarcoma therapy. Front
Bioeng Biotechnol. 10:10426252022. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Yu Y, Li K, Peng Y, Zhang Z, Pu F, Shao Z
and Wu W: Tumor microenvironment in osteosarcoma: From cellular
mechanism to clinical therapy. Genes Dis. 12:1015692025. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Hu J, Lazar AJ, Ingram D, Wang WL, Zhang
W, Jia Z, Ragoonanan D, Wang J, Xia X, Mahadeo K, et al: Cell
membrane-anchored and tumor-targeted IL-12 T-cell therapy destroys
cancer-associated fibroblasts and disrupts extracellular matrix in
heterogenous osteosarcoma xenograft models. J Immunother Cancer.
12:e0069912024. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Loi G, Stucchi G, Scocozza F, Cansolino L,
Cadamuro F, Delgrosso E, Riva F, Ferrari C, Russo L and Conti M:
Characterization of a bioink combining extracellular matrix-like
hydrogel with osteosarcoma cells: Preliminary results. Gels.
9:1292023. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Fan J, Xie Y, Liu D, Cui R, Zhang W, Shen
M and Cao L: Crosstalk between H-type vascular endothelial cells
and macrophages: A potential regulator of bone homeostasis. J
Inflamm Res. 18:2743–2765. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Lee C, Kim MJ, Kumar A, Lee HW, Yang Y and
Kim Y: Vascular endothelial growth factor signaling in health and
disease: From molecular mechanisms to therapeutic perspectives.
Signal Transduct Target Ther. 10:1702025. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Shah FH, Nam YS, Bang JY, Hwang IS, Kim
DH, Ki M and Lee HW: Targeting vascular endothelial growth
receptor-2 (VEGFR-2): Structural biology, functional insights, and
therapeutic resistance. Arch Pharm Res. 48:404–425. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Corre I, Verrecchia F, Crenn V, Redini F
and Trichet V: The osteosarcoma microenvironment: A complex but
targetable ecosystem. Cells. 9:9762020. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Liu K, Ren T, Huang Y, Sun K, Bao X, Wang
S, Zheng B and Guo W: Apatinib promotes autophagy and apoptosis
through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma. Cell Death
Dis. 8:e30152017. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Lammli J, Fan M, Rosenthal HG, Patni M,
Rinehart E, Vergara G, Ablah E, Wooley PH, Lucas G and Yang SY:
Expression of vascular endothelial growth factor correlates with
the advance of clinical osteosarcoma. Int Orthop. 36:2307–2313.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Li Y, Lin S, Xie X, Zhu H, Fan T and Wang
S: Highly enriched exosomal lncRNA OIP5-AS1 regulates osteosarcoma
tumor angiogenesis and autophagy through miR-153 and ATG5. Am J
Transl Res. 13:4211–4223. 2021.PubMed/NCBI
|
|
92
|
Assi T, Watson S, Samra B, Rassy E, Le
Cesne A, Italiano A and Mir O: Targeting the VEGF pathway in
osteosarcoma. Cells. 10:12402021. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Wang C, Duan L, Zhao Y, Wang Y and Li Y:
Efficacy and safety of bevacizumab combined with temozolomide in
the treatment of glioma: A systematic review and meta-analysis of
clinical trials. World Neurosurg. 193:447–460. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Han X, Qin S, Liu S and Li Z:
Intracavitary perfusion with bevacizumab plus cisplatin versus
cisplatin alone for malignant pleural effusion in lung cancer
patients: A meta-analysis of randomized controlled trials. World J
Surg Oncol. 23:2782025. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Lowery CD, Blosser W, Dowless M, Renschler
M, Perez LV, Stephens J, Pytowski B, Wasserstrom H, Stancato LF and
Falcon B: Anti-VEGFR2 therapy delays growth of preclinical
pediatric tumor models and enhances anti-tumor activity of
chemotherapy. Oncotarget. 10:5523–5533. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Haibe Y, Kreidieh M, El Hajj H, Khalifeh
I, Mukherji D, Temraz S and Shamseddine A: Resistance mechanisms to
anti-angiogenic therapies in cancer. Front Oncol. 10:2212020.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Zhou J, Lan F, Liu M, Wang F, Ning X, Yang
H and Sun H: Hypoxia inducible factor-1α as a potential therapeutic
target for osteosarcoma metastasis. Front Pharmacol.
15:13501872024. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Ren K, Zhang J, Gu X, Wu S, Shi X, Ni Y,
Chen Y, Lu J, Gao Z, Wang C and Yao N: Migration-inducing gene-7
independently predicts poor prognosis of human osteosarcoma and is
associated with vasculogenic mimicry. Exp Cell Res. 369:80–89.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Zhang QJ, Liu CH, Wang K, Mao XY, Dong Y,
Zang MY, Zhang W, Yu QS and Hao L: Hypoxia-induced HIF-1α/VASN
promotes bladder cancer progression. Sci Rep. 15:216352025.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Zeng X, Liu S, Yang H, Jia M, Liu W and
Zhu W: Synergistic anti-tumour activity of ginsenoside Rg3 and
doxorubicin on proliferation, metastasis and angiogenesis in
osteosarcoma by modulating mTOR/HIF-1α/VEGF and EMT signalling
pathways. J Pharm Pharmacol. 75:1405–1417. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Vander Heiden MG and DeBerardinis RJ:
Understanding the intersections between metabolism and cancer
biology. Cell. 168:657–669. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Huang Y, Fan H and Ti H: Tumor
microenvironment reprogramming by nanomedicine to enhance the
effect of tumor immunotherapy. Asian J Pharm Sci.
19:1009022024.PubMed/NCBI
|
|
103
|
Zhu L, Lin Z, Wang K, Gu J, Chen X, Chen
R, Wang L and Cheng X: A lactate metabolism-related signature
predicting patient prognosis and immune microenvironment in ovarian
cancer. Front Endocrinol (Lausanne). 15:13724132024. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Zhang D, Tang Z, Huang H, Zhou G, Cui C,
Weng Y, Liu W, Kim S, Lee S, Perez-Neut M, et al: Metabolic
regulation of gene expression by histone lactylation. Nature.
574:575–580. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Lee DC, Sohn HA, Park ZY, Oh S, Kang YK,
Lee KM, Kang M, Jang YJ, Yang SJ, Hong YK, et al: A lactate-induced
response to hypoxia. Cell. 161:595–609. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Wu Q, You L, Nepovimova E, Heger Z, Wu W,
Kuca K and Adam V: Hypoxia-inducible factors: Master regulators of
hypoxic tumor immune escape. J Hematol Oncol. 15:772022. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Mortezaee K and Majidpoor J: The impact of
hypoxia on immune state in cancer. Life Sci. 286:1200572021.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Feng Q, Liu Z, Yu X, Huang T, Chen J, Wang
J, Wilhelm J, Li S, Song J, Li W, et al: Lactate increases stemness
of CD8 + T cells to augment anti-tumor immunity. Nat Commun.
13:49812022. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Kumagai S, Koyama S, Itahashi K,
Tanegashima T, Lin YT, Togashi Y, Kamada T, Irie T, Okumura G, Kono
H, et al: Lactic acid promotes PD-1 expression in regulatory T
cells in highly glycolytic tumor microenvironments. Cancer Cell.
40:201–218.e9. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
He G, Nie JJ, Liu X, Ding Z, Luo P, Liu Y,
Zhang BW, Wang R, Liu X, Hai Y and Chen DF: Zinc oxide
nanoparticles inhibit osteosarcoma metastasis by downregulating
β-catenin via HIF-1α/BNIP3/LC3B-mediated mitophagy pathway. Bioact
Mater. 19:690–702. 2023.PubMed/NCBI
|
|
111
|
Zheng C, Li R, Zheng S, Fang H, Xu M and
Zhong L: The knockdown of lncRNA DLGAP1-AS2 suppresses osteosarcoma
progression by inhibiting aerobic glycolysis via the miR-451a/HK2
axis. Cancer Sci. 114:4747–4762. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Wang Z, Ma L, Xu J and Jiang C: Editorial:
Genetic and cellular heterogeneity in tumors. Front Cell Dev Biol.
12:15195392024. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Oh JM, Park Y, Lee J and Shen K:
Microfabricated organ-specific models of tumor microenvironments.
Annu Rev Biomed Eng. 27:307–333. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Yu Z, Gan Z, Wu W, Sun X, Cheng X, Chen C,
Cao B, Sun Z and Tian J: Photothermal-triggered extracellular
matrix clearance and dendritic cell maturation for enhanced
osteosarcoma immunotherapy. ACS Appl Mater Interfaces.
16:67225–67234. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Rodrigues J, Sarmento B and Pereira CL:
Osteosarcoma tumor microenvironment: The key for the successful
development of biologically relevant 3D in vitro models. In Vitro
Model. 1:5–27. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Liu X, Fang J, Huang S, Wu X, Xie X, Wang
J, Liu F, Zhang M, Peng Z and Hu N: Tumor-on-a-chip: From
bioinspired design to biomedical application. Microsyst Nanoeng.
7:502021. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Spalato M and Italiano A: The safety of
current pharmacotherapeutic strategies for osteosarcoma. Expert
Opin Drug Saf. 20:427–438. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Lu J, Tang H, Chen L, Huang N, Hu G, Li C,
Luo K, Li F, Liu S, Liao S, et al: Association of survivin positive
circulating tumor cell levels with immune escape and prognosis of
osteosarcoma. J Cancer Res Clin Oncol. 149:13741–13751. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Nasir I, McGuinness C, Poh AR, Ernst M,
Darcy PK and Britt KL: Tumor macrophage functional heterogeneity
can inform the development of novel cancer therapies. Trends
Immunol. 44:971–985. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Sharma A, Raut SS, Shukla A, Gupta S,
Mishra A and Singh A: From tissue architecture to clinical
insights: Spatial transcriptomics in solid tumor studies. Semin
Oncol. 52:1523892025. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Alnaqbi H, Becker LM, Mousa M, Alshamsi F,
Azzam SK, Emini Veseli B, Hymel LA, Alhosani K, Alhusain M, Mazzone
M, et al: Immunomodulation by endothelial cells: Prospects for
cancer therapy. Trends Cancer. 10:1072–1091. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Li Y, Huang Z and Yin Y: Heterogeneity of
tumor-associated macrophages in colorectal cancer: Origins,
classification, and immunotherapeutic implications. Pathol Res
Pract. 272:1560822025. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Xu C, Yang J, Xiong H, Cui X, Zhang Y, Gao
M, He L, Fang Q, Han C, Liu W, et al: Machine learning and
multi-omics analysis reveal key regulators of proneural-mesenchymal
transition in glioblastoma. Sci Rep. 15:197312025. View Article : Google Scholar : PubMed/NCBI
|
